[Form 4] PagerDuty, Inc. Insider Trading Activity

Rhea-AI Filing Summary

RAPT Therapeutics, Inc. (RAPT) – Form 4 insider filing

On June 21 2025, director Ashley L. Dombkowski received a new equity award consisting of 25,000 non-qualified stock options with an exercise price of $7.43 per share. The options were reported under transaction code “A” (grant) and are held directly by the reporting person.

Vesting schedule: the grant vests in three equal annual installments over a three-year period starting from the grant date (i.e., approximately 8,333 options per year through June 21 2028). The options expire on June 21 2035.

Following this award, Dombkowski beneficially owns 25,000 derivative securities (stock options). No open-market purchases or sales of common stock were reported, and there were no changes in non-derivative share ownership.

The filing reflects routine director compensation and does not include any other material transactions or earnings information.

Positive

• Aligns director incentives with long-term shareholder value via a 10-year option grant.
• Three-year vesting encourages continued board service and strategic continuity.

Negative

• No open-market share purchase; the filing does not indicate additional insider cash investment.
• Potential albeit minimal dilution if options are exercised in the future.

Insights

Equity Compensation Analyst

TL;DR: Director granted 25k options at $7.43; routine, modest alignment, neutral market impact.

This Form 4 records a single, standard director stock-option grant. At-the-money awards with decade-long terms and three-year vesting are typical for biotech boards. While the grant aligns the director’s incentives with shareholders, it does not involve cash outlay or immediate share accumulation, so signaling value is limited. With only 25,000 options, dilution is immaterial relative to RAPT’s 33 million share base. Overall impact on valuation or float is negligible.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRANKLIN SARAH JOYCE

(Last) (First) (Middle)

600 TOWNSEND STREET, SUITE 200

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PagerDuty, Inc. [ PD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		A		12,416(1)	A	$0	33,287(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 12,416 Restricted Stock Units acquired pursuant to the Issuer's Non-Employee Director compensation policy. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock of the Issuer and has no expiration date. The shares underlying the Restricted Stock Unit award shall fully vest on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting of stockholders, subject to Directors' continuous service to the Issuer on such date.

2. A portion of these shares represent restricted stock units.

Remarks:

	/s/ Irving Gomez, Attorney-in Fact For: Sarah J. Franklin	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RAPT director Ashley Dombkowski report on the latest Form 4?

She received 25,000 stock options at an exercise price of $7.43 on June 21 2025.

When do the newly granted RAPT options vest?

They vest in three equal annual installments over the three-year period beginning June 21 2025.

What is the expiration date of the RAPT stock-option grant?

The options expire on June 21 2035.

Did the director buy or sell RAPT common shares in this filing?

No. The Form 4 shows only an option grant; there were no purchases or sales of common stock.

How many derivative securities does the director own after the transaction?

Ashley Dombkowski now holds 25,000 derivative securities (stock options) directly.